Loading...
XNAS
APLS
Market cap2.13bUSD
May 30, Last price  
16.93USD
1D
-2.76%
1Q
-32.68%
IPO
20.93%
Name

Apellis Pharmaceuticals Inc

Chart & Performance

D1W1MN
P/E
—
P/S
3.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
14.77%
Rev. gr., 5y
%
Revenues
710m
+79.01%
0000000250,646,00066,563,00075,422,000396,591,000709,954,000
Net income
-198m
L-62.57%
-3,961,568-10,788,483-46,515,956-27,124,637-51,006,094-127,502,194-309,815,909-344,874,000-746,354,000-652,172,000-528,628,000-197,878,000
CFO
-88m
L-85.23%
-3,444,652-9,946,917-18,855,947-26,003,078-46,595,073-131,240,797-211,135,445-160,488,000-563,126,000-513,745,000-594,735,000-87,866,000
Earnings
Jul 30, 2025

Profile

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
URL
https://apellis.com/
IPO date
Nov 09, 2017
Employees
767
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
709,954
79.01%
396,591
425.83%
75,422
13.31%
Cost of revenue
445,293
913,712
670,035
Unusual Expense (Income)
NOPBT
264,661
(517,121)
(594,613)
NOPBT Margin
37.28%
Operating Taxes
1,162
2,132
669
Tax Rate
0.44%
NOPAT
263,499
(519,253)
(595,282)
Net income
(197,878)
-62.57%
(528,628)
-18.94%
(652,172)
-12.62%
Dividends
Dividend yield
Proceeds from repurchase of equity
4,512
384,387
384,358
BB yield
-0.11%
-5.41%
-7.00%
Debt
Debt current
13,506
6,441
5,625
Long-term debt
479,985
122,382
127,065
Deferred revenue
Other long-term liabilities
7,972
242,129
315,647
Net debt
82,201
(223,476)
(419,111)
Cash flow
Cash from operating activities
(87,866)
(594,735)
(513,745)
CAPEX
(403)
(773)
(1,524)
Cash from investing activities
(403)
(674)
59,893
Cash from financing activities
149,241
394,499
365,659
FCF
232,773
(688,328)
(594,099)
Balance
Cash
411,290
352,299
551,801
Long term investments
Excess cash
375,792
332,469
548,030
Stockholders' equity
(3,038,662)
(2,841,018)
(2,309,724)
Invested Capital
3,751,710
3,388,596
2,907,956
ROIC
7.38%
ROCE
37.12%
EV
Common stock shares outstanding
123,904
118,678
106,114
Price
31.91
-46.69%
59.86
15.76%
51.71
9.37%
Market cap
3,953,777
-44.34%
7,104,065
29.47%
5,487,155
37.47%
EV
4,035,978
6,880,589
5,068,044
EBITDA
266,458
(515,417)
(593,126)
EV/EBITDA
15.15
Interest
40,391
29,581
32,626
Interest/NOPBT
15.26%